Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.

Neuro-oncology - 1 Dec 2009

Armstrong Terri S, Cao Yumei, Scheurer Michael E, Vera-Bolaños Elizabeth, Manning Rochelle, Okcu Mehmet F, Bondy Melissa, Zhou Renke, Gilbert Mark R

Abstract excerpt

A benefit of temozolomide (TMZ) is that myelotoxicity is uncommon. Recently, several small series have reported significant myelotoxicity resulting in treatment delays or death. The ability to predict risk of myelotoxicity may influence patient care. We retrospectively reviewed 680 malignant glioma patients and developed a clinical risk formula for myelotoxicity for each gender by logistic regression. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Dacarbazine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutathione S-Transferase pi

Share to NAD(P)H Dehydrogenase (Quinone)

Share to Neutropenia

Share to O(6)-Methylguanine-DNA Methyltransferase

Share to Temozolomide

Share to Thrombocytopenia

Source

Open in PubMed Open full text

Identifiers

PMID: 19179423
DOI: 10.1215/15228517-2008-120
PMCID: PMC2802402

Genes

GSTP1
MGMT
NQO1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.PMID 19179423Read ↗

Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.Semantic proximity Read ↗

Clinical and genetic predictors of temozolomide-induced severe myelotoxicity in adult diffuse glioma: a case-control study.Semantic proximity Read ↗

MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.Semantic proximity Read ↗

Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients.Semantic proximity Read ↗

Genetic associations of docetaxel-based chemotherapy-induced myelosuppression in Chinese Han population.Semantic proximity Read ↗

Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study.Semantic proximity Read ↗

Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.Semantic proximity Read ↗

Genetic predisposition and treatment-related leukemia.Semantic proximity Read ↗

Patient profiling for treatment toxicity: potential use of clinical and genomic factors.Semantic proximity Read ↗

Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastomaSemantic proximity Read ↗

Genome-wide association study of epirubicin-induced leukopenia in Japanese patients.Semantic proximity Read ↗

A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.